MDX-214 consists of recombinant human epidermal growth factor (EGF) genetically linked to a fully human antibody fragment that is designed to activate cytotoxic killing of cancer cells by immune effector... It is developed for the treatment of EGF-R overexpressing cancers.
- Mechanism
- Curator reviewed
MDX-214 is believed to target the epidermal growth factor receptor (EGFr), a receptor molecule implicated in tumor cell growth and found to be over- expressed in a variety of cancers, including head and neck, breast, colon, prostate, lung and ovarian cancers. Preclinical in vitro studies conducted by Medarex suggest that MDX-214 may provide an unusually potent approach to treating EGFr-positive cancers by inhibiting tumor cell growth and by mediating antibody-dependent cellular cytotoxicity (ADCC).
- Primary indication
- Investigated for use/treatment in cancer/tumors (unspecified).Curator reviewed
- Code names
- MDX-214
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with MDX-214, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account